Drug Interaction Report
1 potential interaction and/or warning found for the following 2 drugs:
- Besremi (ropeginterferon alfa-2b)
- chloramphenicol
Interactions between your drugs
chloramphenicol ropeginterferon alfa-2b
Applies to: chloramphenicol, Besremi (ropeginterferon alfa-2b)
GENERALLY AVOID: Coadministration of chloramphenicol with other agents that can cause bone marrow depression, aplastic anemia, or agranulocytosis may increase the risk and/or severity of hematologic toxicity. Serious and fatal blood dyscrasias (aplastic anemia, hypoplastic anemia, thrombocytopenia, granulocytopenia, and bone marrow depression) have been reported after short-term and long-term systemic therapy with chloramphenicol.
MANAGEMENT: Concurrent use of chloramphenicol with other agents that can cause bone marrow depression, aplastic anemia, or agranulocytosis, such as sulfonamides, nucleoside reverse transcriptase inhibitors, procainamide, phenylbutazone, clozapine, and depot formulations of antipsychotic drugs, should be avoided.
References (4)
- (2002) "Product Information. Chloromycetin (chloramphenicol)." Parke-Davis
- (2022) "Product Information. Chloromycetin (chloramphenicol)." Pfizer Canada Inc
- (2015) "Product Information. Chloromycetin Succinate (chloramphenicol)." Link Medical Products Pty Ltd T/A Link Pharmaceuticals
- (2023) "Product Information. Chloramphenicol (chloramphenicol)." Eramol (UK) Ltd
Drug and food/lifestyle interactions
No alcohol/food interactions were found with the drugs in your list. However, this does not necessarily mean no food interactions exist. Always consult your healthcare provider.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Report options
- Switch to consumer interaction data
- Email this report to a friend, doctor, or patient
- Ask questions, find answers
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Jakafi
Jakafi is used to treat certain types of myelofibrosis or polycythemia vera in adults, and certain ...
Intron A
Intron A is used for angioblastoma, condylomata acuminata, conjunctival mucosa-associated lymphoid ...
Botox
Botox is used cosmetically to reduce facial lines and wrinkles and for medical purposes for ...
PegIntron
PegIntron is used to treat chronic hepatitis C in adults. Learn about side effects, interactions ...
Sylatron
Sylatron (peginterferon alfa-2b) used to prevent malignant melanoma from coming back after it has ...
Ropeginterferon alfa-2b
Ropeginterferon alfa-2b is used for polycythemia vera
Peginterferon alfa-2b
Peginterferon alfa-2b is used for chronic myelogenous leukemia, hepatitis b, hepatitis c, melanoma ...
Interferon alfa-2b
Interferon alfa-2b is used for angioblastoma, condylomata acuminata, conjunctival mucosa-associated ...
Ruxolitinib
Ruxolitinib (oral) is used to treat certain types of myelofibrosis (MF), polycythemia vera (PV) ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.